Palisade Bio doses first patient in global Phase 2b ASCENTRA-UC trial of PALI-2108

Palisade Bio announced the first patient has been dosed in its global Phase 2b ASCENTRA-UC clinical trial, evaluating PALI-2108, an investigational once-daily oral PDE4 inhibitor prodrug, in approximately 204 patients with moderately to severely active ulcerative colitis.

Detected & updated continuously · Source: Nebula